Ludwig Enterprises, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
Ludwig Enterprises, an early-stage genomic diagnostics company, reported significant losses and a going concern warning in its 2025 annual report, despite advancing its Revealia Breast test towards a Q2 2026 trial launch.
OID
Ludwig Enterprises, Inc. reports its annual results for 2024, highlighting its focus on developing mRNA-based genomic technology for early detection of inflammatory diseases.
OID
Ludwig Enterprises Inc. released its 2023 annual report, detailing its focus on mRNA technology for disease detection and treatment, while also acknowledging significant financial losses and a going concern warning.